New Delhi :

Jubilant Biosys Ltd, a Bangalore-based subsidiary of Jubilant Life Sciences Ltd, said the USFDA had accepted its IND (Investigational New Drug) filing for a ‘novel’ molecule targeting prostate cancer with Endo Pharmaceuticals of the US.

This molecule would now progress toward the next phase of development and is anticipated to go into clinical trials by late 2013, a company release said.

Subir Kumar Basak, President, Global Drug Discovery Services, Jubilant Life Sciences, said the “successful outcome” was the result of collaboration between the scientists at Endo (a US-based specialty healthcare company) and Jubilant Biosys.

source: http://www.thehindubusinessline.com / Business Line / Home> Companies / by The Hindu Bureau / New Delhi – August 07th, 2013